Syngene International Ltd
NSE:SYNGENE
Intrinsic Value
Syngene International Ltd. operates as a global discovery, development and manufacturing organization providing integrated scientific services to the pharmaceutical, biotechnology, nutrition, animal h... [ Read More ]
The intrinsic value of one
SYNGENE
stock under the Base Case scenario is
582.28
INR.
Compared to the current market price of 718.35 INR,
Syngene International Ltd
is
Overvalued by 19%.
Syngene International Ltd's market capitalization is 287.4B INR.
SYNGENE stock price is 718.35 INR.
SYNGENE stock (582.28 INR) is 19% less than its price (718.35 INR).
SYNGENE stock (215.67 INR) is 70% less than its price (718.35 INR). Open DCF Valuation
SYNGENE stock price (718.35 INR) is 24% less than its Relative Value (948.89 INR). Open Relative Valuation
SYNGENE has upside potential of 6% compared to the average analyst price target.
Open Wall St Estimates
SYNGENE has positive three-year average ROIC (Return on Invested Capital): 11%. The company is efficient at using invested capital to generate operating income.
SYNGENE's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 13%.
SYNGENE's ROIC (Return on Invested Capital) has increased in the last 3 years from 11% to 13%.
SYNGENE's ROE (Return on Equity) has decreased in the last 3 years from 16% to 14%.
SYNGENE's ROE (Return on Equity) for the past 12 months is positive and is equal to 14%.
SYNGENE's Revenue has grown by an exceptional 21% over the past 12 months.
SYNGENE has positive Net Income for the last twelve months.
SYNGENE has positive three-year average ROE (Return on Equity): 14%. The company is efficient at transforming stockholders' equity into net income.
SYNGENE has positive Operating Income for the last twelve months.
SYNGENE's Revenue is forecast to grow at a rate of 16% per year over the next 3 years.
SYNGENE has positive Free Cash Flow for the last twelve months.
SYNGENE's Revenue has been growing by 19% per year for the last 3 years.
SYNGENE's short-term assets (24B INR) exceed its short-term liabilties (12B INR).
SYNGENE has positive Gross Profit for the last twelve months.
SYNGENE's long-term assets (58B INR) exceed its long-term liabilties (20B INR).
SYNGENE has negative Net Debt. This means that the company has more cash and short-term investments (15B INR) than debt (4B INR).
SYNGENE's D/E (Debt to Equity) is very low and is equal to 0.11.
SYNGENE earns more than enough operating income (7B INR) to safely cover interest payments on its debt (419m INR).
SYNGENE's Altman Z-Score is very high and is equal to 10.35.
Valuation Backtest
Syngene International Ltd
Run backtest to discover the historical profit from buying and selling
SYNGENE
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Syngene International Ltd
Balance Sheet Decomposition
Syngene International Ltd
| Current Assets | 23.7B |
| Cash & Short-Term Investments | 15.1B |
| Receivables | 4.2B |
| Other Current Assets | 4.5B |
| Non-Current Assets | 34.7B |
| Long-Term Investments | 1.7B |
| PP&E | 29.2B |
| Intangibles | 249m |
| Other Non-Current Assets | 3.6B |
| Current Liabilities | 12.3B |
| Accounts Payable | 2.8B |
| Other Current Liabilities | 9.5B |
| Non-Current Liabilities | 7.3B |
| Long-Term Debt | 4.2B |
| Other Non-Current Liabilities | 3.1B |
Earnings Waterfall
Syngene International Ltd
|
Revenue
|
35.7B
INR
|
|
Cost of Revenue
|
-10.2B
INR
|
|
Gross Profit
|
25.4B
INR
|
|
Operating Expenses
|
-18.9B
INR
|
|
Operating Income
|
6.5B
INR
|
|
Other Expenses
|
-1.5B
INR
|
|
Net Income
|
5B
INR
|
Free Cash Flow Analysis
Syngene International Ltd
What is Free Cash Flow?
SYNGENE Profitability Score
Profitability Due Diligence
Syngene International Ltd's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
Score
Syngene International Ltd's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
SYNGENE Solvency Score
Solvency Due Diligence
Syngene International Ltd's solvency score is 85/100. The higher the solvency score, the more solvent the company is.
Score
Syngene International Ltd's solvency score is 85/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SYNGENE Price Targets Summary
Syngene International Ltd
According to Wall Street analysts, the average 1-year price target for
SYNGENE
is 760.67 INR
with a low forecast of 686.8 INR and a high forecast of 851.55 INR.
Shareholder Return
SYNGENE Price
Syngene International Ltd
| Average Annual Return | 24.08% |
| Standard Deviation of Annual Returns | 48.46% |
| Max Drawdown | -37% |
| Market Capitalization | 287.4B INR |
| Shares Outstanding | 400 172 054 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Syngene International Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Syngene International Ltd. operates as a global discovery, development and manufacturing organization providing integrated scientific services to the pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical industries. The company is headquartered in Bangalore, Karnataka and currently employs 5,975 full-time employees. The company went IPO on 2015-08-11. The firm is engaged in providing services from early discovery and development to commercial manufacturing for small and large molecules. Its services include drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process research and development, current good manufacturing practice (cGMP) manufacturing, formulation and analytical development along with clinical development services. The company offers SynVent, a therapeutic discovery and development platform for executing drug discovery projects, which is designed to provide a range of advance programs through target validation, translational interrogation, therapeutic discovery and preclinical development for both large and small molecules, as well as specialty modalities, such as targeted protein degradation. The company serves clients ranging from multinational corporations to start-ups.
Contact
IPO
Employees
Officers
The intrinsic value of one
SYNGENE
stock under the Base Case scenario is
582.28
INR.
Compared to the current market price of 718.35 INR,
Syngene International Ltd
is
Overvalued by 19%.
You don't have any saved screeners yet
